Publication of Groundbreaking Study on Ultra-Sensitive Molecular Residual Disease Detection in EMBO Molecular Medicine

August 20, 2024

The study showed 90% sensitivity and 100% specificity in colorectal cancer patient blood samples collected within six weeks after surgery.

AccuraGen Highlights New Developments in MRD Detection with AccuScan Whole-Genome Sequencing Solution

September 6, 2024

AccuraGen is gaining attention in the medical community for its innovative approach to minimal residual disease (MRD) detection.

Collaborator Presented New Data at ESMO 2019 Congress

October 9, 2019

Dr. Tao Fu presented new data as a poster at the ESMO 2019 Congress.

Several Collaborator Presented Research Result of Different Cancers

September 5, 2019

Several Collaborator Presented Research Result of Different Cancers

Collaborator Presented Research Result on Small Methods Journal

August 30, 2019

Research result conducted by Professor Jiatao Lou recently published on Small Methods.

Collaborator presented AccuraGen's ctDNA-NGS kit validation at AACR

April 25, 2018

The study was conducted by Professor Jiatao Lou, director of the Chest Hospital.

AccuraGen was invited to PMWC to showcase the latest achievements in liquid biopsy

January 29, 2018

The Precision Medicine World Conference (PMWC) of 2018 was held in Silicon Valley from January 22 to 24 in the United States.

Science Overview

Blood as a window to our health


We have been understanding our health through a number of blood tests in a large spectrum of scenarios; ranging from diabetes to heart attack, from pregnancy to cancer. We track proteins, circulating DNA, miRNA, etc

AccuScan for MRD

With the advancement of technology, we can now capture and digitize analytes in our blood quantitatively. AccuScan is the whole genome sequencing technology we built with many years of efforts to accurately convert signals from circulating tumor DNA to infer tumor load of an individual.

Multi-analytes modeling


By gathering multi-omics information from a large population of healthy and cancer cohort, we train with the state-of-the-art machine learning algorithm to differentiate cancer and healthy status of an individual. 

Transforming cancer management

The potential applications of liquid biopsy are vast - from targeted cancer therapy selection to real-time minimal residual disease monitoring to population-level early screening - and we believe it will play a critical role in the future of cancer management. With more clinical studies that we're collecting, we will show clincal utility for different applications. For the next person coming to our clinic, we will take a snapshot with his blood and try to catch cancer in a stage that can be treated.